VMware vSAN is the hyperconverged storage backbone for a significant portion of pharmaceutical research infrastructure worldwide. From high-throughput screening platforms in drug discovery to clinical data repositories and validated LIMS storage tiers, vSAN's software-defined architecture has made it the default choice for organisations that need enterprise-grade storage without the complexity of external SAN arrays. The Broadcom acquisition changed the commercial dynamics of vSAN in ways that most pharmaceutical IT teams have not yet fully absorbed.
Under the new VCF (VMware Cloud Foundation) model, vSAN is no longer licenced as a standalone product in most scenarios. Its inclusion in the VCF bundle creates a pricing and scoping problem for pharmaceutical organisations that deployed vSAN on targeted research clusters — often without the full vSphere management stack that VCF requires. This article examines how the new licence model applies to pharmaceutical research environments and what organisations should do to protect their position before a Broadcom audit or renewal engagement.
How vSAN Licensing Changed Under Broadcom
Prior to the acquisition, VMware offered vSAN in tiered editions (Standard, Advanced, Enterprise, Enterprise Plus) licenced per CPU socket. Organisations could purchase vSAN independently of other VMware products and deploy it on any hardware that met VMware HCL requirements. This flexibility made vSAN attractive as a storage-layer replacement in environments where vSphere was already deployed.
Broadcom's restructured portfolio eliminated the standalone vSAN SKU for new purchases. VCF is now the primary commercial vehicle, and vSAN is included within it alongside vSphere, NSX, and vCenter. The practical consequence for pharmaceutical organisations is that any new vSAN deployment, any expansion of existing vSAN clusters, or any transition from perpetual to subscription licencing now carries an obligation to evaluate whether full VCF coverage is required.
The per-core pricing model compounds this change. A vSAN cluster supporting a pharmaceutical bioinformatics platform with four compute nodes, each carrying 32-core processors, now requires VCF licensing for 256 cores. The same cluster under the old per-socket model required eight socket licences. For current generation processors, the per-core model typically represents a cost increase of 180 to 350 percent depending on the edition tier.
The Redress Compliance Broadcom practice works exclusively with organisations navigating this transition, providing licence position analysis, cost modelling, and commercial negotiation support for vSAN deployments at every scale.
Research-Specific vSAN Use Cases and Licence Implications
Pharmaceutical research environments create specific vSAN deployment patterns that generate unique licence questions under the new model. Understanding which use cases carry the highest risk helps prioritise remediation effort.
Genomics and sequencing data storage. Next-generation sequencing platforms generate datasets of 100GB to 1TB per sample run. Many pharmaceutical organisations have deployed vSAN all-flash clusters as the primary storage tier for raw sequencing data, processed FASTQ files, and aligned BAM files. These clusters often run entirely separately from validated GxP infrastructure, but Broadcom's audit scope typically covers the entire vSphere estate regardless of the functional classification of individual clusters.
High-performance computing storage for molecular modelling. Computational drug discovery platforms using platforms such as Schrodinger, OpenEye, or internal HPC environments require low-latency, high-throughput storage. vSAN NVMe-backed clusters are commonly deployed for this use case with large core counts per node. These deployments represent some of the highest cost exposure under per-core pricing due to the dense compute configurations used.
Validated LIMS and ELN storage tiers. Laboratory Information Management Systems and Electronic Laboratory Notebooks that are GxP-validated frequently use vSAN as their underlying storage layer. The VMware audit defence challenges specific to pharmaceutical organisations are most acute in these validated environments, where storage configuration changes require formal change control and potential revalidation before any licence remediation can be implemented.
Disaster recovery vSAN clusters. Pharmaceutical organisations commonly deploy vSAN ROBO (Remote Office / Branch Office) or stretched cluster configurations for DR of validated systems. Under the old model, DR clusters could often be licenced at reduced rates through specific DR licence provisions. Under VCF, the licence treatment of DR clusters is less clear, and Broadcom's position during audits has been to require full per-core VCF coverage for all DR nodes that host production VMs, even during failover testing.
Key Licence Entitlement Questions for vSAN
Before engaging in any Broadcom audit response or renewal negotiation, pharmaceutical organisations should resolve several specific licence entitlement questions for their vSAN deployments.
What version of the vSAN EULA governed your original purchase? Perpetual licence agreements signed before October 2023 typically reference a specific product licence rather than the VCF suite. The extent to which Broadcom can enforce VCF-level pricing obligations on pre-acquisition perpetual licences is commercially contestable, particularly where the perpetual EULA includes a perpetual use right that does not automatically convert to a subscription obligation.
Do your vSAN deployments include NSX or vCenter components that trigger VCF bundling requirements? Broadcom's position is that organisations using vCenter to manage vSAN clusters alongside NSX for network virtualisation are effectively running VCF and should be licenced accordingly. Whether this position holds under the specific terms of older ELAs is a legal question that requires careful review before accepting it as a given during audit discussions.
Are any vSAN clusters deployed on hardware not on the current VMware HCL? Server refresh cycles in pharmaceutical environments are often longer than the typical three to five year enterprise IT cycle due to validation requalification costs. Hardware that was on the HCL at the time of vSAN deployment may have since been removed. Broadcom has used HCL compliance as a secondary leverage point in negotiations, so understanding your hardware position before engaging is important.
What is the correct scope of your DR coverage obligation? The entitlement to use perpetual DR licences, ROBO licences, or reduced-rate provision for DR nodes should be verified against the specific licence documentation for each deployment. Broadcom's audit teams assert full-rate coverage for DR nodes as an opening position; the actual contractual obligation varies significantly by agreement vintage and structure.
vSAN and Data Integrity Under Pharmaceutical Regulatory Standards
For pharmaceutical organisations, vSAN deployments supporting validated systems have a dimension that purely commercial licence discussions do not capture: the obligation to maintain validated storage configurations under 21 CFR Part 11, EU Annex 11, and GAMP 5 guidelines. This regulatory overlay creates constraints on how quickly vSAN licence issues can be remediated and what forms of remediation are permissible.
Data integrity requirements under ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) impose specific obligations on the storage systems that hold audit trails, batch records, and analytical data. A vSAN configuration change that affects RAID policy, deduplication settings, or encryption configuration must be validated before it can be deployed in a GxP environment. This means that moving from a vSAN Standard deployment to a VCF-aligned vSAN configuration is not simply a software upgrade, it is a validated infrastructure change with its own project timeline.
Understanding this constraint is central to any realistic negotiation with Broadcom over vSAN licence remediation timelines. Organisations that can document the regulatory timeline for infrastructure changes in validated environments have a defensible basis for requesting extended transition periods and licence bridges that cover the gap between commercial agreement and validated deployment. Our VMware Negotiation Playbook includes templates for documenting revalidation timelines in commercial negotiations.
vSAN Cost Optimisation Strategies for Pharma
Despite the significant cost increases associated with the VCF model, pharmaceutical organisations have meaningful levers available to reduce vSAN spend if they engage before Broadcom sets the negotiation terms.
Cluster architecture right-sizing. Many pharmaceutical vSAN clusters were sized to meet storage capacity requirements using a mix of large-core compute nodes. Under per-core pricing, the compute configuration directly drives the licence cost. Evaluating whether research workloads can be consolidated to fewer, more storage-dense nodes with lower core counts per socket reduces the licence base before the VCF transition. This architectural change requires validation planning for GxP clusters but can be completed within a managed change control process.
Separating research and validated storage tiers. Non-validated research storage workloads have more flexibility for infrastructure change than GxP-validated systems. Organisations that clearly separate their validated and non-validated vSAN clusters can negotiate different transition timelines and potentially different commercial terms for each population, rather than treating the entire estate as a single homogeneous upgrade requirement.
Evaluating vSAN alternatives for non-validated workloads. For genomics data storage and HPC scratch tiers that are not subject to GxP validation requirements, alternatives such as Nutanix, pure-play NFS, or object storage on commodity hardware provide credible alternatives to vSAN. Demonstrating that you have evaluated and begun procurement processes for alternatives significantly improves your position in VCF negotiations, as it signals that Broadcom faces a genuine risk of losing non-validated workloads entirely.
Leveraging multi-year commitment for rate reduction. For validated vSAN clusters that must remain on VMware infrastructure due to the cost of revalidating migrations to alternative platforms, multi-year VCF subscriptions provide leverage for meaningful rate reductions. Deals agreed in 2025 benchmark at 25 to 40 percent below Broadcom's published list pricing when supported by a three to five year commitment across a significant core count. The Redress Compliance benchmarking service provides pharmaceutical organisations with current deal data before they enter negotiations.
The Broader Broadcom Impact on Pharmaceutical Software Portfolios
vSAN is not the only Broadcom software asset creating commercial pressure for pharmaceutical organisations. The acquisition brought CA Technologies and Symantec products into the Broadcom portfolio alongside VMware, and Broadcom's post-acquisition commercial approach has been consistent across all three product families: consolidate SKUs, require subscription conversion, and apply audit pressure to drive renewals.
Pharmaceutical organisations using CA Workload Automation, CA IDMS, or Symantec Endpoint Security should expect the same commercial dynamics as vSAN renewals. Our guide to Broadcom software licensing for pharmaceutical organisations covers the full portfolio impact beyond VMware, including the specific compliance risks arising from CA Technologies mainframe software in GxP environments.
Action Plan for Pharmaceutical vSAN Managers
The combination of Broadcom's subscription conversion drive, the per-core pricing model, and the VCF bundling requirement creates a time-sensitive commercial problem for pharmaceutical vSAN operators. The organisations that secure the best outcomes are those that move first with a coherent strategy rather than waiting for Broadcom to define the terms of the conversation.
Complete a vSAN estate inventory that documents every cluster, node count, core count per node, edition licenced, licence vintage, and GxP validation status. This inventory should be prepared by your licence management function with input from the validation team, not extracted directly from vCenter and submitted to Broadcom. The format and content of data you provide in a licence audit materially affects the findings and the subsequent commercial discussion.
Identify the two or three largest vSAN clusters by core count. These represent the majority of your financial exposure and should be the focus of your negotiation preparation. For each cluster, determine whether the workload is validated or non-validated, whether any hardware is approaching end of support life, and whether there are credible architectural alternatives that could inform your negotiation position.
Engage a specialist adviser before Broadcom initiates formal contact. The Broadcom Knowledge Hub at Redress Compliance provides current intelligence on Broadcom audit tactics, VCF negotiation benchmarks, and pharmaceutical-specific commercial structures. For organisations ready to discuss their specific situation, our team can be engaged for a confidential initial review at no cost.